Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: The in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters

Drug Metabolism and Disposition

Volumn 44, Issue 3, 2016, Pages 453-459

  Vermeer, Lydia M M ^a   Isringhausen, Caleb D ^a   Ogilvie, Brian W ^a   Buckley, David B ^a  

^a XenoTech LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; CLARITHROMYCIN; DRUG METABOLITE; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETOCONAZOLE; KETOITRACONAZOLE; MEMBRANE PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN; N DESALKYLITRACONAZOLE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; RITONAVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNCLASSIFIED DRUG; CARRIER PROTEIN; CYTOCHROME P450 3A INHIBITOR;

ARTICLE; DRUG MECHANISM; DRUG SCREENING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MEMBRANE VESICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL LINE; DRUG INTERACTION; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CELL LINE; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MEMBRANE TRANSPORT PROTEINS; RITONAVIR;

EID: 84959018708     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067744     Document Type: Article

References (50)

1. Ahlin G, Chen L, Lazorova L, Chen Y, Ianculescu AG, Davis RL, Giacomini KM, and Artursson P (2011) Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 11:400-411.
2. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, and Evers R; International Transporter Consortium (2013) In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 94:95-112.
3. Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, and Sirtori C (2004) Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers. Pharmacol Res 49:493-499.
4. Cho SK, Kim CO, Park ES, and Chung JY (2014) Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol 78:1426-1432.
5. Cui Y, König J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
6. Davey PG (1991) The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 19 (Suppl A):29-37.
7. European Medicines Agency (2012) Guideline on the Investigation of Drug Interactions. (Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf). Accessed: October 8, 2015.
8. European Medicines Agency (2013) European Medicines Agency Recommends Suspension of Marketing Authorizations for Oral Ketoconazole: Benefit of Oral Ketoconazole Does Not Outweigh Risk of Liver Injury in Fungal Infections. (Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/07/WC500146613.pdf). Accessed: September 9, 2015.
9. FDA-Center for Drug Evaluation and Research (2012) Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. (Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf). Accessed: October 8, 2015.
10. FDA-Center for Drug Evaluation and Research (2013a) FDA Advises Against Using Oral Ketoconazole in Drug Interaction Studies Due to Serious Potential Side Effects. (Available at: http://www.fda.gov/Drugs/DrugSafety/ucm371017.htm). Accessed: September 9, 2015.
11. FDA-Center for Drug Evaluation and Research (2013b) FDA Drug Safety Communication: FDA Limits Usage of Nizoral (ketoconazole) Oral Tablets Due to Potentially Fatal Liver Injury and Risk of Drug Interactions and Adrenal Gland Problems. (Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362444.pdf). Accessed: September 9, 2015.
12. FDA-Center for Drug Evaluation and Research (2014) Nizoral Label and Approval History. (Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory#apphist). Accessed: September 9, 2015.
13. Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, and Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 83:567-576.
14. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, and Sandmann S (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372-380.
15. Greenblatt DJ (2015) Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. J Clin Pharmacol DOI: 10.1002/jcph.609 [published ahead of print].
16. Greenblatt DJ and Harmatz JS (2015) Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol 80: 342-350.
17. Greenblatt HK and Greenblatt DJ (2014) Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol 54:1321-1329.
18. Gurley BJ, Swain A, Williams DK, Barone G, and Battu SK (2008) Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 52:772-779.
19. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665.
20. Herédi-Szabá K, Palm JE, Andersson TB, Pál Á, Méhn D, Fekete Z, Beéry E, Jakab KT, Jani M, and Krajcsi P (2013) A P-gp vesicular transport inhibition assay: optimization and validation for drug-drug interaction testing. Eur J Pharm Sci 49:773-781.
21. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, and Sugiyama Y (2013) Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17b-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab Dispos 41:1859-1866.
22. Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O, Kusuhara H, and Sugiyama Y (2015) Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43:235-247.
23. Jaakkola T, Backman JT, Neuvonen M, and Neuvonen PJ (2005) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 77:404-414.
24. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94: 1140-1146.
25. Jalava KM, Partanen J, and Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613.
26. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, and Zamek-Gliszczynski MJ; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80-94.
27. Kaukonen KM, Olkkola KT, and Neuvonen PJ (1997) Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 62:510-517.
28. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, and Hall SD (2014) Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther 95:473-476.
29. Keogh JP and Kunta JR (2006) Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27:543-554.
30. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379-386.
31. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, and Unadkat JD (2012) Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 40: 610-616.
32. Kuroha M, Azumano A, Kuze Y, Shimoda M, and Kokue E (2002) Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metab Dispos 30:63-68.
33. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, and Grunfeld C (2004) The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 18:641-649.
34. Lilja JJ, Niemi M, Fredrikson H, and Neuvonen PJ (2007) Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 63:732-740.
35. Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, Rogge M, Stoch SA, and Robertson SM (2015) Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J Clin Pharmacol DOI: 10.1002/jcph.562 [published ahead of print].
36. Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel K-D, Burhenne J, Weiss J, Mikus G, and Haefeli WE (2014) Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. Br J Clin Pharmacol 77:141-148.
37. Matsson EM, Eriksson UG, Palm JE, Artursson P, Karlgren M, Lazorova L, Brännström M, Ekdahl A, Dunér K, and Knutson L, et al. (2013) Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. Mol Pharm 10:4252-4262.
38. Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, Okudaira N, and Izumi T (2014) Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos 42:520-528.
39. Müller F, Pontones CA, Renner B, Mieth M, Hoier E, Auge D, Maas R, Zolk O, and Fromm MF (2015) N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. Eur J Clin Pharmacol 71:85-94.
40. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55: 481-485.
41. Reddy YS, Ford SL, Anderson MT, Murray SC, Ng-Cashin J, and Johnson MA (2007) Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. Antimicrob Agents Chemother 51:1202-1208.
42. Shitara Y, Takeuchi K, and Horie T (2013) Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. J Pharm Sci 102:3427-3435.
43. Tateishi T, Miura M, Suzuki T, and Uno T (2008) The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 65:693-700.
44. Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, and Lee CA (2011) Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodiumdependent transporter expressed in HEK293 cells. Drug Metab Dispos 39:2093-2102.
45. Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2010) Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 88:499-505.
46. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77-85.
47. University of Washington (2015) UW Metabolism and Transport Drug Interaction Database. (Available at: http://www.druginteractioninfo.org/). Accessed: October 8, 2015.
48. Van Tyle JH (1984) Ketoconazole: mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 4:343-373.
49. Varhe A, Olkkola KT, and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56: 601-607.
50. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, and Nagar S, et al.; International Transporter Consortium (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transportmediated PK and DDIs in humans. Clin Pharmacol Ther 94:64-79.